Lymphoma Clinical Trials

DIFFUSE LARGE B-CELL LYMPHOMA: (4)
1) 2ND line or greater/ SGN35-031: A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

2) CTMX-M-2029-001 (CytomX) A Phase 1-2, First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas.

3) MOR208C310 frontMIND: A Phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of Tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate, and high-risk patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL)

4)NDS-DLBCL-003 Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study: The Connect® Lymphoma Disease Registry is a US-based, multicenter, prospective observational (non-interventional) cohort study designed to collect real-world, patient-level data longitudinally in patients diagnosed with various subtypes of NHL. The study will consist of 4 cohorts, as described in detail below: 1) patients with first R/R DLBCL who have initiated second-line (2L) systemic treatment; 2) patients with second R/R DLBCL who have initiated third line (3L) systemic treatment; 3) patients with first R/R FL who have initiated 2L systemic treatment; and 4) patients with first R/R PMBCL who have initiated 2L systemic treatment.

FOLLICULAR LYMPHOMA Grade 1 to 3a or R/R Marginal Zone Lymphoma (2)
1) INCMOR 0208-301 inMIND: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma.

2) NDS-DLBCL-003 Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study: The Connect® Lymphoma Disease Registry is a US-based, multicenter, prospective observational (non-interventional) cohort study designed to collect real-world, patient-level data longitudinally in patients diagnosed with various subtypes of NHL. The study will consist of 4 cohorts, as described in detail below: 1) patients with first R/R DLBCL who have initiated second-line (2L) systemic treatment; 2) patients with second R/R DLBCL who have initiated third line (3L) systemic treatment; 3) patients with first R/R FL who have initiated 2L systemic treatment; and 4) patients with first R/R PMBCL who have initiated 2L systemic treatment.